Publications (for a fully updated list, visit PubMed)

Maharaj, K.; Powers, J. J.; Achille, A.; Mediavilla-Varela, M.; Gamal, W.; Burger, K. L.; Fonseca, R.; Jiang, K.; Miskin, H. P.; Maryanski, D.; Monastyrskyi, A.; Duckett, D. R.; Roush, W. R.; Cleveland, J. L.; Sahakian, E.; Pinilla-Ibarz, J., The dual PI3Kdelta/CK1epsilon inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cells. Blood Adv 2020, 4 (13), 3072-3084.

Vena, F.; Bayle, S.; Nieto, A.; Quereda, V.; Aceti, M.; Frydman, S.; Sansil, S.; Grant, W.; Monastyrskyi, A.; McDonald, P.; Roush, W.; Teng, M.; Duckett, D.; Targeting casein kinase 1 delta sensitizes pancreatic and bladder cancer cells to gemcitabine treatment by upregulating deoxycytidine kinase. Molecular Cancer Therapeutics. 2020 Pubmedid: 32430484

Quereda, V., Bayle, S., Vena, F., Monastyrskyi, A., Roush, W., and Duckett, D. Therapeutic Targeting of CDK12/CDK13 in Triple-Negative Breast Cancer, 2019, Cancer Cell 36, 545-558.



Publications (before Moffitt)

Monastyrskyi, A.; Bayle, S.; Quereda, V.; Grant, W.; Cameron, M.D.; Duckett, D.R.; Roush, W.R.  Discovery of 2-arylquinazoline derivatives as a new class of ASK1 inhibitors. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 400-404.

Monastyrskyi, A.; Nilchan, N.; Quereda, V.; Noguchi, Y.; Ruiz, C.; Grant, W.; Cameron, M.D.; Duckett, D.R.; Roush, W.R.  Development of Dual Casein Kinase 1δ/1ε (CK1δ/ε) Inhibitors for Treatment of Breast Cancer, Bioorganic and Medicinal Chemistry, 2018, 26, 590-602.

Neelarapu, R.; Maignan, J.R.; Lichorowic, C.L.; Monastyrskyi, A.; LaCrue, A.N.; Mutka, T.S.; Blake, L.D.; Casandra, D.; Mashkouri, S.; Burrows, J.B.; Willis, P.A.; Kyle, D.E.; Manetsch, R. Design and synthesis of orally bioavailable piperazine substituted 4(1H)-quinolones with potent antimalarial activity: structure-activity and structure-property relationship studies, Journal of Medicinal Chemistry, 2017,61 (4), 1450-1473.

Namelikonda, N.K.; Monastyrskyi, A.; Manetsch, R. Gram scale synthesis of antimalarial 4(1H)-quinolones ELQ-300 and P4Q-391. European Journal of Organic Chemistry, 2017, 23, 3328-3334.

Monastyrskyi, A.; Namelikonda, N.K.; Manetsch, R. Metal-free arylation of ethyl acetoacetate with hypervalent diaryliodonium salts: an immediate access to diverse 3‑aryl-4(1H)‑quinolones. Journal of Organic Chemistry 2015, 80, 2513−2520.

Cross, R.M.; Flanigan, D.L.; Monastyrskyi, A.; LaCrue, A.N.; Maignan, J.M.; Mutka, T. S.; Guida, C.W.; White, K.L., Charman, S.A., Burrows, J.N.; Kyle, D. E.; Manetsch, R. Orally bioavailable 6-chloro-7-methoxy-4(1H)-quinolones efficacious against multiple stages of Plasmodium. Journal of Medicinal Chemistry 2014, 57 (21), 8860–8879.

Monastyrskyi, A.; Kyle, D. E.; Manetsch, R. 4(1H)-Pyridone and 4(1H)-quinolone derivatives as antimalarials with erythrocytic, exoerythrocytic, and transmission blocking activities. Current Topics in Medicinal Chemistry, 2014, 14, 1693-1705.

LaCrue, A. N.; Saenz, F. E.; Cross, R. M.; Udenze, K. O.; Monastyrskyi, A.; Stein, S.; Mutka, T. S.; Manetsch, R.; Kyle, D. E. 4(1H)-Quinolones with liver stage activity against Plasmodium berghei. Antimicrobial Agents and Chemotherapy, 2013, 57, 417-24.

Cross, R. M.; Monastyrskyi, A.; Mutka, T. S.; Burrows, J. N.; Kyle, D. E.; Manetsch, R. Endochin optimization: structure-activity and structure-property relationship studies of 3-substituted 2-methyl-4(1H)-quinolones with antimalarial activity. Journal of Medicinal Chemistry, 2010, 53, 7076-94. 



Manetsch, R.; Kyle, D.E.; Monastyrskyi, A.; LaCrue, A.L.; Maignan, J.R.; Brockmeyer, F.M. Compounds and methods for their use in the treatment of malaria. 2019, US2019/031613

Manetsch, R.; Kyle, D.; Monastyrskyi, A.; LaCrue, A.; Maignan, J. Compounds and methods for their use in the treatment of malaria. 2017, WO2017127820A1.

Riscoe, M. K.; Kelly, J. X.; Winter, R. W.; Hinrichs, D. J.; Smilkstein, M. J.; Nilsen, A.; Burrows, J.; Kyle, D.; Manetsch, R.; Cross, R. M.; Monastyrskyi, A.; Flanigan, D.L. Compounds having antiparasitic or anti-infectious activity. 2013,WO2012167237